Lestaurtinib
A tyrosine kinase inhibitor used in cancer treatment
Lestaurtinib is a small molecule tyrosine kinase inhibitor that has been investigated for its potential use in the treatment of various types of cancer. It is particularly noted for its activity against the FLT3 receptor, which is often mutated in certain types of leukemia.
Mechanism of Action[edit | edit source]
Lestaurtinib functions by inhibiting the activity of tyrosine kinases, which are enzymes that play a critical role in the signaling pathways that regulate cell division and survival. By blocking these enzymes, lestaurtinib can interfere with the growth and proliferation of cancer cells. The drug is particularly effective against the FLT3 receptor, a common mutation in acute myeloid leukemia (AML) that leads to uncontrolled cell growth.
Clinical Applications[edit | edit source]
Lestaurtinib has been studied in clinical trials for its efficacy in treating acute myeloid leukemia (AML), especially in patients with FLT3 mutations. It has also been explored for use in other malignancies, including acute lymphoblastic leukemia (ALL) and certain solid tumors. However, its development has faced challenges, and it is not currently approved for general clinical use.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of lestaurtinib involves its absorption, distribution, metabolism, and excretion. It is administered orally and undergoes hepatic metabolism. The drug's half-life and bioavailability are important considerations in its dosing regimen.
Side Effects[edit | edit source]
As with many cancer therapies, lestaurtinib can cause a range of side effects. Common adverse effects include gastrointestinal disturbances, fatigue, and hematological abnormalities such as neutropenia and thrombocytopenia. Monitoring and managing these side effects is crucial in patients undergoing treatment.
Research and Development[edit | edit source]
Lestaurtinib has been the subject of numerous clinical trials aimed at assessing its safety and efficacy. While initial results have shown promise, further research is needed to fully understand its potential and to optimize its use in combination with other therapies.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
